


ACL Laboratories COVID-19 and Influenza Activity Report

Updated: Sep 26, 2021



| RESPIRATORY PATHOGEN PANEL Sep 26, 2021 Positivity Rate (%) | | | | | | | | | | | | | | | | | | | | | | | |
|---|----------------|-----------------|----------------|-----------------|-------|-------|-------|--------------|-----------|-----------|-----------|-----------|----------------|----------------|----------------|----------------|----------------|-----------------|-------|------|----------------|---------------|----------------|
| MONTH | FLU A Total | FLU A (H1N1) | 2009 (H1N1) | FLU A (H3N2) | FLU B | RSV A | RSV B | RSV Total | PARA 1 | PARA 2 | PARA 3 | PARA 4 | Corona 229E | Corona NL63 | Corona OC43 | Corona HKU1 | Meta pneumo | Entero Rhino | ADENO | BOCA | Legio nella | Chla mydia | Myco plasma |
| JAN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.1 | 0.7 | 0.3 | 0.0 | 0.0 | 0.0 |
| FEB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 | 0.2 | 6.1 | 0.2 | 0.3 | 0.0 | 0.0 | 0.0 |
| MAR | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.4 | 0.1 | 0.1 | 0.3 | 0.1 | 1.4 | 0.9 | 0.1 | 0.4 | 12.2 | 1.2 | 0.3 | 0.0 | 0.1 | 0.1 |
| APR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.2 | 0.5 | 0.0 | 0.0 | 2.5 | 2.9 | 0.0 | 0.8 | 15.3 | 1.4 | 1.2 | 0.0 | 0.0 | 0.0 |
| MAY | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.7 | 3.9 | 0.0 | 0.2 | 1.4 | 3.9 | 0.0 | 0.0 | 14.4 | 1.7 | 1.4 | 0.2 | 0.0 | 0.1 |
| JUN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 1.8 | 1.9 | 0.0 | 0.3 | 9.6 | 0.0 | 0.3 | 0.4 | 2.4 | 0.0 | 0.1 | 15.8 | 1.1 | 1.8 | 0.0 | 0.0 | 0.1 |
| JUL | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 7.2 | 8.2 | 0.1 | 0.5 | 12.9 | 0.0 | 0.1 | 0.4 | 1.4 | 0.0 | 0.5 | 18.9 | 1.6 | 4.4 | 0.4 | 0.0 | 0.0 |
| AUG | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 12.7 | 13.5 | 0.0 | 1.3 | 6.2 | 0.1 | 0.1 | 0.1 | 0.5 | 0.0 | 0.6 | 14.1 | 1.3 | 3.9 | 0.0 | 0.0 | 0.0 |
| SEP | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 11.1 | 11.9 | 0.0 | 0.8 | 2.1 | 0.4 | 0.0 | 0.0 | 0.3 | 0.0 | 0.7 | 22.7 | 0.9 | 4.1 | 0.1 | 0.0 | 0.1 |
| OCT | | | | | | | | | | | | | | | | | | | | | | | |
| NOV | | | | | | | | | | | | | | | | | | | | | | | |
| DEC | | | | | | | | | | | | | | | | | | | | | | | |
| MEAN 2019/202 | NA | 0.0 | 1.5 | 0.4 | 0.4 | NA | NA | 2.3 | 0.3 | 0.0 | 0.8 | 0.2 | 0.2 | 0.4 | 0.6 | 0.1 | 2.1 | 6.5 | 0.9 | 0.6 | 0.1 | 0.0 | 0.2 |
| STD 2019/2020 | NA | 0.0 | 2.4 | 0.9 | 0.8 | NA | NA | 3.4 | 0.5 | 0.1 | 1.3 | 0.3 | 0.4 | 0.6 | 1.3 | 0.2 | 2.1 | 3.1 | 0.7 | 0.4 | 0.2 | 0.1 | 0.2 |


Increased prevalence of viruses: **Rhinovirus and RSV**




ACL RSV PCR remains the same , EIA pos rate is trending down

CDC Data RSV pos rate for Region 5 Chicago - (PCR - **23%↑**, Antigen - **33% ↓**)

Total PCR Tests




Total Antigen Tests




| SARS-COV-2 | | | | | Influenza - no activity | | | | RSV (Antigen+PCR) | | | |
|------------|----------------|----------------|---------------|---------------|-------------------------|----------------|---------------|---------------|-------------------|---------------|----------------|----------------|
| Week | IL % SCVPCR | WI % SCVPCR | IL % COVAG | WI % COVAG | IL % FLUPCR | WI % FLUPCR | IL % FLUAG | WI % FLUAG | IL % RSVAG | WI % RSVAG | IL % RSVPCR | WI % RSVPCR |
| Sep 26 | 5.0 | 8.1 | 4.4 | 15.2 | 0 | 0 | 0 | 0 | 27.7 | 35.9 | 30.0 | 37.7 |
| Sep 18 | 4.9 | 9.0 | 7.2 | 17.5 | 0 | 0 | 0 | 0 | 33.0 | 31.0 | 28.0 | 39.6 |
| Sep 12 | 6.5 | 9.6 | 5.9 | 20.5 | 0 | 0 | 0 | 0 | 20.0 | 21.9 | 41.6 | 43.7 |
| Sep 5 | 6.2 | 8.3 | 7.0 | 22.4 | 0 | 0 | 0 | 0 | 33.3 | 43.9 | 38.1 | 40.5 |
| Aug 29 | 7.5 | 8.5 | 9.0 | 21.3 | 0 | 0 | 0 | 0 | 38.9 | 32.5 | 43.9 | 38.8 |
| Aug 22 | 6.0 | 7.3 | 13.5 | 16.1 | 0 | 0 | 0 | 0 | 31.3 | 27.1 | 32.5 | 20.6 |
| Aug 15 | 6.6 | 6.8 | 9.8 | 18.0 | 0 | 0 | 0 | 0 | 22.9 | 23.5 | 27.0 | 16.7 |
| Aug 8 | 6.8 | 7.4 | 9.8 | 15.8 | 0 | 0 | 0 | 0 | 16.6 | 22.7 | 25.7 | 16.9 |
| Aug 1 | 3.8 | 6.9 | 10.5 | 17.6 | 0 | 0 | 0 | 0 | 14.9 | 20.0 | 0.0 | 0.0 |
| Jul 25 | 2.7 | 4.1 | 8.0 | 11.8 | 0 | 0 | 0 | 0 | 15.5 | 16.7 | 0.0 | 0.0 |
| Jul 18 | 1.8 | 2.6 | 1.4 | 7.2 | 0 | 0 | 0 | 0 | 15.6 | 21.6 | 0.0 | 0.0 |
| Jul 11 | 1.6 | 1.6 | 1.0 | 5.0 | 0 | 0 | 0 | 0 | 16.7 | 17.4 | 0.0 | 0.0 |
| Jul 4 | 1.6 | 1.4 | 0.0 | 3.0 | 0 | 0 | 0 | 0 | 15.5 | 15.5 | 0.0 | 0.0 |

ACL RSV tests results are consistent with “atypical” RSV outbreak


ACL COVAG and SCVPCR - Pos rate (%) - Sep 26, 2021



Sep 22, 2021 - daily COVID-19 cases in US - CDC



Sep 18, 2021 – SARS-CoV-2 circulating in the US (~98.4% % Delta variants)



US vaccination status CDC | Data as of: Sep 23, 2021

387,821,704

Vaccines Administered

212,564,346

People who received at
least one dose

182,587,334

People who are fully
vaccinated*


64%

Percentage of the US
population that has
received at least one
dose

55%



Percentage of the US
population that has
been fully vaccinated*

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, September 27, 2020 – September 18, 2021



2020-21 Influenza Season Week 37 ending Sep 18, 2021

ILI Activity Level



According to the WHO's August 2021 influenza update, global flu activity has remained at **lower than expected levels** for this time of year, which they believe may be due to continued COVID-19 measures like physical distancing and masking. (**Flu B and Flu A H3**)


What's New for 2021-2022 - A few things are different for the 2021-2022 influenza (flu) season, including:

The composition of flu vaccines has been updated.

1. All flu vaccines will be **quadrivalent (four component)** for four different flu viruses.
2. Flucelvax Quadrivalent is now approved for people **2 years and older**.
3. **Flu and COVID-19** vaccines can be given at the same time.
4. Guidance concerning contraindications and precautions for the use of two flu vaccines – **Flucevax and Flublok Quadrivalent** – were updated.


CSF targets positivity rate is 5.4%

ACL RMEPNL - CSF POSITIVE TARGETS - Sep 26, 2021



The most prevalent GI bacterial target is (Cryptosporidium 1.0%)

ACL GPP - STOOL POS BACTERIAL TARGETS - Sep 26, 2021



The most prevalent GI viral target is – (Norovirus II – 0.5%)

